Phase 3 Clinical Trials With Primary Completion Dates in May 2025
This is a list of Phase 3 trials with primary completion dates in May 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| DBVT | DBV Technologies S.A. | 2025-05-01 | Phase 3 | NCT03859700 | Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children |
| DBVTF | DBV TECHNOLOGIES | 2025-05-01 | Phase 3 | NCT03859700 | Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children |
| HLBBF | H. Lundbeck A/S | 2025-05-01 | Phase 3 | NCT03238326 | Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia |
| INZY | Inozyme Pharma, Inc. | 2025-05-01 | Phase 3 | NCT06046820 | The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency |
| MCUJF | Medicure Inc. | 2025-05-01 | Phase 3 | NCT04706013 | Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency |
| REGMF | RemeGen Co., Ltd. | 2025-05-01 | Phase 3 | NCT03330418 | A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders |
| VERA | Vera Therapeutics, Inc. | 2025-05-01 | Phase 3 | NCT04716231 | Atacicept in Subjects With IgA Nephropathy |
| VRDN | Viridian Therapeutics, Inc. | 2025-05-01 | Phase 3 | NCT06179875 | An Open-label Study for Non-responders of VRDN-001-101 and VRDN-001-301 (OLE) |
| VRDN | Viridian Therapeutics, Inc. | 2025-05-01 | Phase 3 | NCT06384547 | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants with Thyroid Eye Disease (TED) |